ClinicalTrials.gg
Status unknownNCT03372850Updated Jan 17, 2018

Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations

A Phase 1 interventional study of HIP1601 and HGP1705 in Healthy, sponsored by Hanmi Pharmaceutical Company Limited. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

This study is a Randomized, Open-label, Multiple Dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1601 (40 mg or 20 mg) to HGP1705 (40 mg or 20 mg) After Multiple Administrations in Healthy Male Volunteers

Read the detailed description

This study is a 2-part study, where in Part A, the 40 mg dose will be performed followed by the 20 mg dose in Part B.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 19\~50 years in healthy male volunteers
  2. is more than 18 kg/m\^2 , no more than 27.0 kg/m\^2
  3. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of in writing

Exclusion criteria

Exclusion Criteria:

  1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
  2. Subjects who judged ineligible by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Sequence Group 1

    Period 1: Reference Drug(HGP1705) Period 2: Test Drug(HIP1601)

    Drug: HIP1601 · Drug: HGP1705

  • Experimental
    Sequence Group 2

    Period 1: Test Drug(HIP1601) Period 2: Reference Drug(HGP1705)

    Drug: HIP1601 · Drug: HGP1705

Interventions

  • Test Drug

    Also known as: Esomeprazole (40 mg or 20 mg)

  • Reference Drug

    Also known as: Nexium(esomeprazole 40 mg or 20 mg)

06

What researchers measure

Primary outcomes

  1. AUClast of esomeprazole

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  2. After 7days of repeated administration, Total gastric acidity decrease rate versus baseline for 24 hours

    pharmacodynamic evaluation

    Time frame: 7Day 24h(Full time) pH monitoring

Secondary outcomes

  1. AUCinf of esomeprazole

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  2. Cmax of esomeprazole

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  3. Tmax of esomeprazole

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  4. Terminal Half-life of esomeprazole

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  5. CL/F of esomeprazole

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  6. Vd/F of esomeprazole

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  7. Ctrough

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 51 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 2 Day 0 hour

  8. Ctrough,ss

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  9. PTF

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  10. RActrough

    pharmacokinetic evaluation

    Time frame: 1 Day 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 4 Day 0 hour, 5 Day 0 hour, 6 Day 0 hour, 7 Day 0 hour, 8 Day 0 hour

  11. After the first administration of esomeprazole, The rate of decrease of integrated gastric acidity compared to baseline for 24 hours

    pharmacodynamic evaluation

    Time frame: 1Day 24h pH monitoring

  12. After the first dose and 7 days of repeated dosing, Percentage of time to maintain gastric pH 4.0 or higher for 24 hours

    pharmacodynamic evaluation

    Time frame: 1Day(Full time) pH monitoring, 7Day 24h(Full time) pH monitoring

  13. After the first administration and 7 days of repeated administration, The median pH measured for 24 hours

    pharmacodynamic evaluation

    Time frame: 1Day(Full time) pH monitoring, 7Day 24h(Full time) pH monitoring

  14. After first administration and 7 days of repeated administration, Total gastric acidity reduction rate versus baseline between 12hours and 24 hours

    pharmacodynamic evaluation

    Time frame: 1Day 12h, 2Day 0h, 7Day 12h, 8Day 0h

  15. After the first dose and 7 days of repeated dosing, Percentage of time to maintain gastric pH 4.0 or higher between 12hours and 24 hours

    pharmacodynamic evaluation

    Time frame: 1Day 12h, 2Day 0h, 7Day 12h, 8Day 0h

  16. After the first dose and 7 days of repeated dosing, The median pH measured between 12hours and 24 hours

    pharmacodynamic evaluation

    Time frame: 1Day (12~24h) pH monitoring, 7Day (12~24h) pH monitoring

Other outcomes

  1. After first administration and repeated administration for 7 days, The percentage of decrease in integrated gastric acidity compared to baseline by time

    exploratory endpoint

    Time frame: 1Day(Full time) pH monitoring, 7Day 24h (Full time) pH monitoring

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
    • Injin Jang, M.D, Ph.D. · Contact
    • In-Jin Jang, Ph.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2018; primary completion for Jun 2018, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2017
First posted
Dec 14, 2017
StartEst.
Feb 15, 2018
Primary completionEst.
Jun 15, 2018
CompletionEst.
Jun 15, 2018
Last update
Jan 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03372850
Responsible party
Sponsor
First posted
Dec 14, 2017
Start date
Feb 15, 2018 (estimated)
Primary completion
Jun 15, 2018 (estimated)
Completion
Jun 15, 2018 (estimated)
Last update
Jan 17, 2018

Study contacts

Sujin Kim, Pharm.D.
Contact
sjk9053@hanmi.co.kr
+821065589053

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Esomeprazole · HGP1705

Start the discussion